- Wednesday, October 4, 2023
8:00 AM – 8:07 AM PT
264 - Efficacy and Toxicity of Different Target Volume Delineations of Radiotherapy Based on the Updated RTOG/NRG and EORTC Guidelines in Patients with High Grade Glioma: A Randomized, Controlled Clinical TLocation: Room 33Presenter: – Hunan Cancer Hospital
Feng Liu, MD – Hunan Cancer Hospital ### 1971964###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Hunan Cancer Hospital###Presenter: – Hunan Cancer Hospital
### 8:10 AM – 8:17 AM PT
265 - Low Dose Fractionated Radiation Therapy as a Chemo-Potentiator of Salvage Temozolomide (TMZ) for Recurrent Anaplastic Astrocytoma (AA) and Glioblastoma Multiforme (GBM): A Single-Arm Phase I/II TrialLocation: Room 33Presenter: – Johns Hopkins University
Timothy Lin, MD, MBA – Johns Hopkins University ### 535807###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Johns Hopkins University###Presenter: – Johns Hopkins University
### 8:20 AM – 8:27 AM PT
266 - Multi-Institutional Report of Re-Irradiation for Recurrent High-Grade GliomaLocation: Room 33Presenter: – Wake Forest Baptist Medical Center
Hosniya Zarabi, MD, MS, BS – Wake Forest Baptist Medical Center ### 1971965###Presenter######Wake Forest Baptist Medical Center###Presenter: – Wake Forest Baptist Medical Center
### 8:30 AM – 8:37 AM PT
267 - Oncogenic Activities of Tribbles1 (TRIB1) Pseudokinase Overexpressed in GBM Are Mediated By Protein-Protein InteractionsLocation: Room 33
Karnika Singh, PhD – OSU CCC ### 1971966###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###OSU CCC###Presenter: – OSU CCC
### 8:40 AM – 8:47 AM PT
268 - A Combined Phase 0/2 "Trigger" Trial of Niraparib in Combination with Radiation in Patients with Newly-Diagnosed GlioblastomaLocation: Room 33Presenter: – Barrow Neurological Institute
William Kennedy, MD – Barrow Neurological Institute ### 2082186###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Barrow Neurological Institute###Presenter: – Barrow Neurological Institute
### 8:50 AM – 9:00 AM PT
DiscussantLocation: Room 33Discussant: – Cleveland Clinic Taussig Cancer Center
Jennifer Yu, MD, PhD – Cleveland Clinic Taussig Cancer Center ### 524586###Discussant###Disclosures: Employment: Cleveland Clinic:Staff:Employee | Compensation: NIH: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: to present ;Cleveland Clinic: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: to present ;Case Comprehensive Cancer Center: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: to present | Ownership: Abbvie:Stock;Medtronics:Stock | Leadership: International Journal of Hyperthermia:Associate Editor;Molecular Carcinogenesis:Associate Editor;Frontiers in Oncology:Associate Editor###Cleveland Clinic Taussig Cancer Center###Discussant: – Cleveland Clinic Taussig Cancer Center
### 8:05 AM – 8:10 AM PT
1206 - Very Low Dose Radiation Therapy for Indolent Lymphomas: Comparing "Big Boom" (4Gy x 1) vs. "Boom Boom" (2Gy x 2)Location: Room 8Presenter: – Memorial Sloan Kettering Cancer Center
Brandon Imber, MD, MS – Memorial Sloan Kettering Cancer Center ### 536050###Presenter###Disclosures: Employment: Memorial Sloan Kettering Cancer Center:Assistant Attending Radiation Oncologist:Employee | Compensation: GT Medical Technologies: Education Meeting Faculty, Honoraria-End Date: November 2021 ;Telix Pharmaceuticals: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Honoraria-End Date: November 2022 | Ownership: none | Leadership: none###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 8:10 AM – 8:15 AM PT
1208 - Distribution and Failure Patterns of Primary Central Nervous System Lymphoma Related to HippocampusLocation: Room 8Presenter: – Seoul National University
Hye-Jo Ryu, MD – Seoul National University ### 1972100###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Seoul National University###Presenter: – Seoul National University
### 8:15 AM – 8:20 AM PT
1210 - Acute Pulmonary Toxicity after Allogeneic Stem Cell Transplantation Using Total Body Irradiation-Based Conditioning- Myeloablative vs. Non-Myeloablative RegimensLocation: Room 8Presenter: – Duke University Medical Center
Christopher Kelsey, MD, FASTRO – Duke University Medical Center ### 524559###Presenter###Disclosures: Employment: Duke University Medical Center:Professor:Employee | Compensation: Johnson and Johnson: Consultant, Compensation Payment-End Date: 12/7/2022 ;Proctor and Gamble: Consultant, Compensation Payment-End Date: 12/7/2022 | Ownership: none | Leadership: none###Duke University Medical Center###Presenter: – Duke University Medical Center
### 8:20 AM – 8:25 AM PT
1212 - Irradiated Extramedullary Acute Myeloid Leukemia Increases Survival in a Leukemic Mouse ModelLocation: Room 8Presenter: – University of Texas MD Anderson Cancer Center
Francisco Saenz, PhD, MS – University of Texas MD Anderson Cancer Center ### 1972101###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of Texas MD Anderson Cancer Center###Presenter: – University of Texas MD Anderson Cancer Center
### 8:25 AM – 8:30 AM PT
1214 - First-in-Human Phase I Trial Combining Biologically Guided Radioimmunotherapy (RIT) Using a 90Y-Anti-CD25 Monoclonal Antibody (Mab) with CT-guided Total Marrow and Lymphoid Irradiation (TMLLocation: Room 8Presenter: – City of Hope National Medical Center
Jeffrey Wong, MD, FASTRO – City of Hope National Medical Center ### 535883###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###City of Hope National Medical Center###Presenter: – City of Hope National Medical Center
### 8:30 AM – 8:35 AM PT
1216 - Long-Term Toxicity after Total Body Irradiation-Based Conditioning Regimens for Allogeneic Stem Cell TransplantationLocation: Room 8Presenter: – Duke University School of Medicine
Pranalee Patel, MD, BS – Duke University School of Medicine ### 1972102###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Duke University School of Medicine###Presenter: – Duke University School of Medicine
### 8:05 AM – 8:10 AM PT
1218 - Failure Mode and Effects Analysis for Treatment Workflow of a Novel Ring Gantry LinacLocation: Room 7Presenter: – University of Pittsburgh, Hillman Cancer Center
Shada Wadi-Ramahi, PhD – University of Pittsburgh, Hillman Cancer Center ### 1971539###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of Pittsburgh, Hillman Cancer Center###Presenter: – University of Pittsburgh, Hillman Cancer Center
### 8:10 AM – 8:15 AM PT
1220 - ACR Accreditation of a Novel Linac-Based kV-CBCT System on a High-Speed Ring-GantryLocation: Room 7Presenter: – New York Proton Center
Allison Haertter, MS – New York Proton Center ### 1972107###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###New York Proton Center###Presenter: – New York Proton Center
### 8:15 AM – 8:20 AM PT
1222 - Dosimetric Comparison of Adaptive Radiotherapy Modalities for Stereotactic Partial Breast IrradiationLocation: Room 7Presenter: – UT Southwestern Medical Center
Yesenia Gonzalez, PhD – UT Southwestern Medical Center ### 746616###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###UT Southwestern Medical Center###Presenter: – UT Southwestern Medical Center
### 8:20 AM – 8:25 AM PT
1224 - Extended Field Radiosurgery of Spinal Metastases with MRI-Guided Adaptive Planning: A Dosimetric StudyLocation: Room 7Presenter: – Sylvester Comprehensive Cancer Center
Beatriz Guevara, MS – Sylvester Comprehensive Cancer Center ### 1972108###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Sylvester Comprehensive Cancer Center###Presenter: – Sylvester Comprehensive Cancer Center
### 8:25 AM – 8:30 AM PT
1226 - Predicting Prostate VMAT 3D Radiation Doses of Continuously Varying Organ Dose Trade-Offs Using a Conditional Variational AutoencoderLocation: Room 7Presenter: – Ohio State University James Cancer Hospital
Simeng Zhu, MD – Ohio State University James Cancer Hospital ### 1972109###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Ohio State University James Cancer Hospital###Presenter: – Ohio State University James Cancer Hospital
### 8:30 AM – 8:35 AM PT
1228 - Brachytherapy Dose Prediction Based on Monte Carlo Simulations Using Artificial Neural NetworksLocation: Room 7Presenter: – Shanghai Sixth People's Hospital
Zhen Li, MS – Shanghai Sixth People's Hospital ### 1972110###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Shanghai Sixth People's Hospital###Presenter: – Shanghai Sixth People's Hospital
### 9:15 AM – 9:45 AM PT
DiscussantLocation: Ballroom 20Discussant: – Dana-Farber Cancer Institute / Harvard Medical School
Kimmie Ng, MD, MPH – Dana-Farber Cancer Institute / Harvard Medical School ### 2087171###Discussant###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Dana-Farber Cancer Institute / Harvard Medical School###Discussant: – Dana-Farber Cancer Institute / Harvard Medical School
### 9:45 AM – 10:15 AM PT
DiscussantLocation: Ballroom 20Discussant: – MD Anderson Cancer Center
Kristy Brock, PhD, FASTRO – MD Anderson Cancer Center ### 524478###Discussant###Disclosures: Employment: The University of Texas MD Anderson Cancer Center:Professor:Employee | Compensation: RaySearch Laboratories: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Research Grants, Research Funding, Research Salary Support,Grant Research Funding-End Date: Present | Ownership: RaySearch Laboratories:Copyright | Leadership: none###MD Anderson Cancer Center###Discussant: – MD Anderson Cancer Center
### 10:30 AM – 10:37 AM PT
269 - More Efficient Auto-Segmentation Framework Using Patient-Specific Information for CBCT-Guided Adaptive RadiotherapyLocation: Room 5Presenter: – ASTRO Show Management
Yuxiang Liu, MS – ASTRO Show Management ### 1971991###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###ASTRO Show Management###Presenter: – ASTRO Show Management
### 10:40 AM – 10:47 AM PT
270 - New Data-Driven Gated (DDG) PET/CT for Radiation Treatment Planning of NSCLCLocation: Room 5Presenter: – MD Anderson Cancer Center
Tinsu Pan, PhD – MD Anderson Cancer Center ### 1971992###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###MD Anderson Cancer Center###Presenter: – MD Anderson Cancer Center
### 10:50 AM – 10:57 AM PT
271 - Failure Mode and Effects Analysis Prior to the Introduction of AI Generated GTVs for Brain Metastases in the Clinical WorkflowLocation: Room 5Presenter: – Memorial Sloan Kettering Cancer Center
Michalis Aristophanous, PhD – Memorial Sloan Kettering Cancer Center ### 1971993###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 11:00 AM – 11:07 AM PT
272 - An Automated Brain Metastasis Detection and Segmentation System from MRI with a Large Multi-Institutional DatasetLocation: Room 5Presenter: – Siemens Healthineers
Youngjin Yoo, PhD – Siemens Healthineers ### 1971994###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Siemens Healthineers###Presenter: – Siemens Healthineers
### 11:10 AM – 11:17 AM PT
273 - Clinical Outcomes of Image-Guided Volumetric Modulated Arc Therapy for Total Body IrradiationLocation: Room 5Presenter: – Arizona Oncology
Sarah Kilic, MD, MS – Arizona Oncology ### 1971995###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Arizona Oncology###Presenter: – Arizona Oncology
### 11:20 AM – 11:27 AM PT
274 - Dosimetric and Clinical Results of a Volumetric-Based Skin-Sparing Planning Technique for Patients Treated to the Breast and Chest Wall with Pencil Beam Scanning Proton TherapyLocation: Room 5Presenter: – Radiation Oncology Associates
Avani Rao, MD – Radiation Oncology Associates ### 524894###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Radiation Oncology Associates###Presenter: – Radiation Oncology Associates
### 10:30 AM – 10:37 AM PT
275 - Patient-Level Savings Using the Mark Cuban Cost Plus Drugs Company for Radiation Oncology PatientsLocation: Room 4Presenter: – MD Anderson Cancer Center
Ramez Kouzy, MD – MD Anderson Cancer Center ### 1972016###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###MD Anderson Cancer Center###Presenter: – MD Anderson Cancer Center
### 10:40 AM – 10:47 AM PT
276 - Clinical Sequalae of Initial Insurance Denials in a Large Academic Radiation Oncology CenterLocation: Room 4Presenter: – Memorial Sloan Kettering Cancer Center
Jacob Shin, MD – Memorial Sloan Kettering Cancer Center ### 537867###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 10:50 AM – 10:57 AM PT
277 - Association of Managed Medicaid Plans and Cancer Stage at DiagnosisLocation: Room 4Presenter: – Washington University School of Medicine
Justin Barnes, MD, MS – Washington University School of Medicine ### 595915###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Washington University School of Medicine###Presenter: – Washington University School of Medicine
### 11:00 AM – 11:07 AM PT
278 - Comparing Changes in Medicare Reimbursement for Radiation Oncology and Medical Oncology (2010-2020)Location: Room 4Presenter: – Washington University in St. Louis School of Medicine
Jacob Hogan, BS – Washington University in St. Louis School of Medicine ### 1972017###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Washington University in St. Louis School of Medicine###Presenter: – Washington University in St. Louis School of Medicine
### 11:10 AM – 11:17 AM PT
279 - Financial Improvements from Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care, "SAVE" TrialLocation: Room 4Presenter: – University of Utah Huntsman Cancer Institute
Cristina DeCesaris, MD – University of Utah Huntsman Cancer Institute ### 538445###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of Utah Huntsman Cancer Institute###Presenter: – University of Utah Huntsman Cancer Institute
### 11:20 AM – 11:27 AM PT
280 - Unplanned Hospitalization and Subsequent Mortality in Lung Cancer Patients Undergoing Concomitant Chemo-/Immuno-Therapy and Radiotherapy: An Analysis of Over 10,000 Patients in a Nationwide DatabaseLocation: Room 4Presenter: – Rutgers Cancer Institute of New Jersey
Jongmyung Kim, MD, PhD – Rutgers Cancer Institute of New Jersey ### 1971978###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Rutgers Cancer Institute of New Jersey###Presenter: – Rutgers Cancer Institute of New Jersey
### 10:35 AM – 10:40 AM PT
1230 - Hybrid Immuno-RT for Bulky Tumors: Standard Fractionation with Partial Tumor SBRTLocation: Room 8Presenter: – Huaxi Hospital
Ren Luo, MD, PhD – Huaxi Hospital ### 2088106###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Huaxi Hospital###Presenter: – Huaxi Hospital
### 10:40 AM – 10:45 AM PT
1232 - Fungal Depletion Bolsters Anti-Tumor Immune Response Elicited by Anti-PD1 Alone and in Combination with Radiation TherapyLocation: Room 8Presenter: – Cedars-Sinai Medical Center
Satchel Stevens, BS – Cedars-Sinai Medical Center ### 1972104###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Cedars-Sinai Medical Center###Presenter: – Cedars-Sinai Medical Center
### 10:45 AM – 10:50 AM PT
1234 - Non-Canonical NF-kB Pathway Suppresses Anti-Tumor Micro-environment and Prompts Pre-Metastasis Niches for Conventional Fractionated RadiotherapyLocation: Room 8
Dawei Chen, MD, MB ### 2029570###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none######Presenter:
### 10:50 AM – 10:55 AM PT
1236 - Irradiated Tumor Cells-derived Exosomes Modulate Macrophage Polarization by Targeting SHP-2 Mediated Metabolic ReprogrammingLocation: Room 8
Dawei Chen, MD, MB ### 2029570###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none######Presenter:
### 10:55 AM – 11:00 AM PT
1238 - Radiation Therapy Sensitizes Head-and-Neck Cancer Cells to Killing by Chimeric Antigen Receptor (CAR)-NK Cells Targeting CD70Location: Room 8Presenter: – MD Anderson Cancer Center
Gohar Manzar, MD, PhD – MD Anderson Cancer Center ### 537790###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###MD Anderson Cancer Center###Presenter: – MD Anderson Cancer Center
### 11:00 AM – 11:05 AM PT
1240 - Malignant Peripheral Nerve Sheath Tumors Activate Distinct Immunosuppressive Pathways Following Radiotherapy and are Associated with Immune Depletion In VivoLocation: Room 8Presenter: – University of California, San Francisco
Iowis Zhu, PhD – University of California, San Francisco ### 1972106###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of California, San Francisco###Presenter: – University of California, San Francisco
### 10:35 AM – 10:40 AM PT
1242 - Evaluation of Pneumonitis in a Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilmumab or Nivolumab Alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB NonLocation: Room 7Presenter: – IU Health Methodist Hospital
Michael Weisman, MD – IU Health Methodist Hospital ### 1972111###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###IU Health Methodist Hospital###Presenter: – IU Health Methodist Hospital
### 10:40 AM – 10:45 AM PT
1244 - A Novel FDG PET and Mean Lung Dose Model to Identify Stage III NSCLC Patients at High Risk of Developing Early Radiation PneumonitisLocation: Room 7Presenter: – Memorial Sloan Kettering Cancer Center
Maria Thor, PhD, MS – Memorial Sloan Kettering Cancer Center ### 535996###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 10:45 AM – 10:50 AM PT
1246 - Association of Cardiac Dose with Cardiac Events and Survival for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) Treated with Concurrent Chemoradiotherapy (cCRT) in the Era of Immune CheckpointLocation: Room 7Presenter: – University of Pennsylvania Health System
Nikhil Yegya-Raman, MD – University of Pennsylvania Health System ### 538407###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of Pennsylvania Health System###Presenter: – University of Pennsylvania Health System
### 10:50 AM – 10:55 AM PT
1248 - Investigating Dosimetry and Imaging Biomarkers for Prediction of Major Adverse Cardiac Events Following Locally Advanced Non-Small Cell Lung Cancer RadiotherapyLocation: Room 7Presenter: – Stanford University
Hyunsoo No, MD, CMD – Stanford University ### 1972112###Presenter###Disclosures: Employment: Stanford University:Resident Physician, Radiation Oncology:Employee | Compensation: RSNA Research & Education Foundation: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: 6/30/2024 ;TED Ed: Other, Honoraria-End Date: to present ;American College of Radiation Oncology: Research Grants, Research Funding, Research Salary Support,Grant Research Funding-End Date: 10/2023 | Ownership: none | Leadership: none###Stanford University###Presenter: – Stanford University
### 10:55 AM – 11:00 AM PT
1250 - Association of Left Ventricular Myocardium Dose Exposure with Heart Failure in Lung Cancer RadiotherapyLocation: Room 7Presenter: – Cedars-Sinai Medical Center
Katelyn Atkins, MD, PhD – Cedars-Sinai Medical Center ### 535835###Presenter###Disclosures: Employment: Cedars-Sinai Medical Center:Assistant Professor:Employee | Compensation: OncLive: Education Meeting Faculty, Honoraria-End Date: 04/2021 | Ownership: none | Leadership: none###Cedars-Sinai Medical Center###Presenter: – Cedars-Sinai Medical Center
### 11:00 AM – 11:05 AM PT
1252 - Long-Term Toxicity in Patients Receiving Radiotherapy for Ultracentral Stage I Non-Small Cell Lung Cancer - A Secondary Analysis of the LUSTRE Randomized TrialLocation: Room 7Presenter: – BC Cancer Agency - Vancouver Island Centre
Che Hsuan David Wu, MD – BC Cancer Agency - Vancouver Island Centre ### 2073997###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###BC Cancer Agency - Vancouver Island Centre###Presenter: – BC Cancer Agency - Vancouver Island Centre
### 10:30 AM – 10:37 AM PT
281 - Health-Related Quality of Life at Five Years for a Randomized Trial of Tri-Modality Therapy with I-125 Brachytherapy, External Beam Radiation Therapy, and Short- vs. Long-Term Androgen Deprivation TheLocation: Room 1Presenter: – National Hospital Organization Tokyo Medical Center
Atsunori Yorozu, MD, PhD – National Hospital Organization Tokyo Medical Center ### 525290###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###National Hospital Organization Tokyo Medical Center###Presenter: – National Hospital Organization Tokyo Medical Center
### 10:40 AM – 10:47 AM PT
282 - Patient-Reported Urinary and Bowel Quality of Life Outcomes Following External Beam Radiotherapy with or without High-Dose-Rate Brachytherapy Boost: Post-Hoc Analyses of TROG 03.04 (RADAR)Location: Room 1Presenter: – Alfred Health Radiation Oncology
Wee Loon Ong, MBBS – Alfred Health Radiation Oncology ### 747114###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Alfred Health Radiation Oncology###Presenter: – Alfred Health Radiation Oncology
### 10:50 AM – 10:57 AM PT
283 - Conditional Risk and Predictive Factors Associated with Late Toxicity for Prostate Cancer Patients Treated with External Beam Radiotherapy Alone on Randomized Trial RTOG 0126Location: Room 1Presenter: – Thomas Jefferson University
Gregory Alexander, MD – Thomas Jefferson University ### 1972023###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Thomas Jefferson University###Presenter: – Thomas Jefferson University
### 11:00 AM – 11:07 AM PT
284 - Late Urinary Toxicity and QOL with Curative Radiotherapy for High-Risk Prostate Cancer: Dose-Effect Relations in the POP-RT Randomized Phase III TrialLocation: Room 1Presenter: – The Christie NHS Foundation Trust
Priyamvada Maitre, MD – The Christie NHS Foundation Trust ### 1972024###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###The Christie NHS Foundation Trust###Presenter: – The Christie NHS Foundation Trust
### 11:10 AM – 11:17 AM PT
285 - Toxicity and Patient Reported Quality of Life after PSMA-PET and mpMRT-Based Focal Dose Escalated Definitive Radiotherapy in Prostate Cancer Patients: 2-Year Follow-Up of the HypoFocal Phase II TrialLocation: Room 1Presenter: – University Medical Center Freiburg
Simon Spohn, MD – University Medical Center Freiburg ### 1972025###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University Medical Center Freiburg###Presenter: – University Medical Center Freiburg
### 11:20 AM – 11:27 AM PT
286 - Patient Reported Outcomes in High-Risk Prostate Cancer Patients with or without Testosterone Recovery after Androgen Deprivation TherapyLocation: Room 1
Abdenour Nabid, MD – CHUS ### 524757###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###CHUS###Presenter: – CHUS
### 11:30 AM – 11:40 AM PT
DiscussantLocation: Room 1Presenter: – University of Michigan
William Jackson, MD – University of Michigan ### 524732###Presenter###Disclosures: Employment: university of michigan:assistant professor:Employee | Compensation: :Role Topic Description-End Date: | Ownership: none | Leadership: none###University of Michigan###Presenter: – University of Michigan
### 10:30 AM – 10:37 AM PT
287 - Treatment Terminations during Radiation Therapy: A Ten-Year ExperienceLocation: Room 2Presenter: – Northwell Health Center for Advanced Medicine
Jason Nosrati, MD – Northwell Health Center for Advanced Medicine ### 1972026###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Northwell Health Center for Advanced Medicine###Presenter: – Northwell Health Center for Advanced Medicine
### 10:40 AM – 10:47 AM PT
288 - Quantitative and qualitative impact of CT-Based Radiotherapy Dose Maps on Radiologists Interpretation of Post-treatment Thoracic Surveillance ImagingLocation: Room 2Presenter: – University of Washington School of Medicine
Kira Newell, BA – University of Washington School of Medicine ### 1972027###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of Washington School of Medicine###Presenter: – University of Washington School of Medicine
### 10:50 AM – 10:57 AM PT
289 - Quality Assurance in a Phase III, Multicenter, Randomized Trial of POstmastectomy radioThErapy in Node posiTive Breast Cancer with or without Internal mAmmary nodaL Irradiation (POTENTIAL): A PlanningLocation: Room 2Presenter: – Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Yuchun Song, MD – Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College ### 1972028###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College###Presenter: – Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
### 11:00 AM – 11:07 AM PT
290 - Reducing Patient Care Delays in Radiation Oncology via Optimization of Insurance Pre-AuthorizationLocation: Room 2
Maxwell Tran, MD – MUSC ### 1972029###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###MUSC###Presenter: – MUSC
### 11:10 AM – 11:17 AM PT
291 - Optimization of Workup Pathways to Decrease Radiotherapy Wait Times and Improving Patient Experience: A Single Center StudyLocation: Room 2
Abdulmajeed Dayyat, MD ### 1972030###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none######Presenter:
### 11:20 AM – 11:27 AM PT
292 - Can We Improve the Quality of Care Delivered to Cervical Cancer Patients? Development of Quality Metrics and Quality Improvement Program at a Single InstitutionLocation: Room 2Presenter: – Cleveland Clinic Taussig Cancer Center
Sudha Amarnath, MD – Cleveland Clinic Taussig Cancer Center ### 524577###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Cleveland Clinic Taussig Cancer Center###Presenter: – Cleveland Clinic Taussig Cancer Center
### 11:30 AM – 11:40 AM PT
DiscussantLocation: Room 2Discussant: – University of California, San Francisco
Manju Sharma, PhD – University of California, San Francisco ### 1972031###Discussant###Disclosures: Employment: UCSF:Assistant Professor:Employee | Compensation: :Role Topic Description-End Date: | Ownership: none | Leadership: none###University of California, San Francisco###Discussant: – University of California, San Francisco
### 12:30 PM – 12:37 PM PT
293 - Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients: Final Results of a Phase I TrialLocation: Room 1Presenter: – Institut Curie
Christophe Le Tourneau, MD, PhD – Institut Curie ### 537457###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Institut Curie###Presenter: – Institut Curie
### 12:40 PM – 12:47 PM PT
294 - Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Locally Advanced Laryngeal/Hypopharyngeal Carcinoma: Preliminary Results of INSIGHT StudyLocation: Room 1Presenter: – Fudan University Shanghai Cancer Center
Xiaomin Ou, MD – Fudan University Shanghai Cancer Center ### 525095###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Fudan University Shanghai Cancer Center###Presenter: – Fudan University Shanghai Cancer Center
### 12:50 PM – 12:57 PM PT
295 - SBRT in 3 Fractions for T1 Glottic CancerLocation: Room 1Presenter: – Regina Elena National Cancer Institute
Giuseppe Sanguineti, MD, Mr – Regina Elena National Cancer Institute ### 524929###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Regina Elena National Cancer Institute###Presenter: – Regina Elena National Cancer Institute
### 1:00 PM – 1:07 PM PT
296 - Identifying a Dose Constraint for the Parotid Ducts: Impact on Patient Reported Xerostomia and Comparison to Conventional Parotid Gland Mean Dose SparingLocation: Room 1Presenter: – University of North Carolina
Shiva Das, PhD – University of North Carolina ### 746639###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of North Carolina###Presenter: – University of North Carolina
### 1:10 PM – 1:17 PM PT
297 - Dose Painting Radiotherapy Guided by Diffusion-Weighted Magnetic Resonance vs. 18F-FDG-PET/CT in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized, Controlled Clinical TrialLocation: Room 1Presenter: – Hunan Cancer Hospital
Feng Liu, MD – Hunan Cancer Hospital ### 1971964###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Hunan Cancer Hospital###Presenter: – Hunan Cancer Hospital
### 1:20 PM – 1:30 PM PT
DiscussantLocation: Room 1Discussant: – University of Michigan
Michelle Mierzwa, MD – University of Michigan ### 746645###Discussant###Disclosures: Employment: University of Michigan:Associate Professor of Radiation Oncology:Employee | Compensation: :Role Topic Description-End Date: | Ownership: none | Leadership: MROQC:Co-lead of Behavioral Health Committee###University of Michigan###Discussant: – University of Michigan
### 12:35 PM – 12:40 PM PT
1254 - Intracranial Control with Combined Dual Immune-Checkpoint Blockade and SRS for Melanoma and NSCLC Brain MetastasesLocation: Room 7Presenter: – Duke Cancer Institute
Eugene Vaios, MD, MBA – Duke Cancer Institute ### 1972114###Presenter###Disclosures: Employment: Duke Cancer Institute:Resident:Employee;Duke Cancer Institute:Fellow:Employee | Compensation: Glasshouse Health: Consultant, Compensation Payment-End Date: Present | Ownership: none | Leadership: none###Duke Cancer Institute###Presenter: – Duke Cancer Institute
### 12:40 PM – 12:45 PM PT
1256 - Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): One-Year Safety and Efficacy Outcomes From a Multicenter Phase I TrialLocation: Room 7Presenter: – University Hospitals Cleveland
Shearwood McClelland, MD – University Hospitals Cleveland ### 537469###Presenter###Disclosures: Employment: University Hospitals Seidman Cancer Center:Director of Spine Oncology:Employee | Compensation: Gilmartin Capital: Consultant, Compensation Payment-End Date: Ongoing ;GT Medical Technologies: Education Meeting Faculty, Travel Expenses-End Date: 2/26/23 | Ownership: none | Leadership: NRG Oncology:Rural Health Special Interest Group;National Medical Association:Research Committee;NRG Oncology:Scientific Core Committee###University Hospitals Cleveland###Presenter: – University Hospitals Cleveland
### 12:45 PM – 12:50 PM PT
1258 - Initial Report of Boswellia Serrata for Management of Cerebral Radiation Necrosis After Stereotactic Radiosurgery for Brain MetastasesLocation: Room 7Presenter: – Ohio State University
Rituraj Upadhyay, MD, MBBS, DNB – Ohio State University ### 746809###Presenter###Disclosures: Employment: The Ohio State University Wexner Medical Center:Resident physician:Employee | Compensation: :Role Topic Description-End Date: | Ownership: none | Leadership: none###Ohio State University###Presenter: – Ohio State University
### 12:50 PM – 12:55 PM PT
1260 - Frameless LINAC-Based Stereotactic Radiosurgery is Safe and Effective for Essential and Parkinsonian TremorLocation: Room 7Presenter: – University of Alabama Birmingham Hospital
Nii-Kwanchie Ankrah, MD – University of Alabama Birmingham Hospital ### 1972116###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of Alabama Birmingham Hospital###Presenter: – University of Alabama Birmingham Hospital
### 12:55 PM – 1:00 PM PT
1264 - Volumetric Modulated Arc Therapy Craniospinal Irradiation Utilizing a Vertebral Body Sparing Approach: A Toxicity AnalysisLocation: Room 7Presenter: – The Ohio State
Jennifer Matsui, PhD – The Ohio State ### 1972849###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###The Ohio State###Presenter: – The Ohio State
### 1:05 PM – 1:10 PM PT
2236 - Feasibility of Cognitive-Sparing Stereotactic Radiosurgery for Brain Metastases: Initial Report of Phase II COG-SRS TrialLocation: Room 7Presenter: – UCSD Radiation Medicine and Applied Sciences
Austin Hopper, MD – UCSD Radiation Medicine and Applied Sciences ### 747811###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###UCSD Radiation Medicine and Applied Sciences###Presenter: – UCSD Radiation Medicine and Applied Sciences
### 12:35 PM – 12:40 PM PT
1266 - Very APBI in 1 or 2 Days: Late Toxicity and Early Oncological Outcomes of the GEC-ESTRO CohortLocation: Room 8
Jean-Michel Hannoun-Levi, MD, PhD ### 1973158###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none######Presenter:
### 12:40 PM – 12:45 PM PT
1268 - Proton vs. Photons for Breast Cancer Patients with Immediate, Implant-Based Reconstruction Receiving Postmastectomy Radiotherapy: A Multicenter Pooled AnalysisLocation: Room 8Presenter: – Massachusets General Hospital
Myrsini Ioakeim-Ioannidou, MD – Massachusets General Hospital ### 575546###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Massachusets General Hospital###Presenter: – Massachusets General Hospital
### 12:45 PM – 12:50 PM PT
1270 - A Phase II Randomized Clinical Trial to Assess Toxicity and Quality of Life of Breast Cancer Patients with Hypofractionated vs. Conventional Fractionation Radiotherapy with Regional Nodal IrradiationLocation: Room 8Presenter: – Rede Mater Dei
Gabriel Gil, MD, PhD, MBA, MS – Rede Mater Dei ### 1973159###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Rede Mater Dei###Presenter: – Rede Mater Dei
### 12:50 PM – 12:55 PM PT
1272 - Cardiological Safety of 5-Fraction Whole Breast IrradiationLocation: Room 8
Lorenzo Livi, MD ### 1973160###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none######Presenter:
### 12:55 PM – 1:00 PM PT
1274 - Pattern and Complication of Reconstructed Breast Cancer Patients Who Received Postmastectomy Radiotherapy in the National Health Insurance Service CohortLocation: Room 8Presenter: – Seoul National University
Hye-Jo Ryu, MD – Seoul National University ### 1972100###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Seoul National University###Presenter: – Seoul National University
### 1:00 PM – 1:05 PM PT
1276 - Identification and Dosimetric Analysis of Axillary Substructures Associated with Breast Cancer Related LymphedemaLocation: Room 8
Jia-Qi Huang ### 1973161###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none######Presenter:
### 12:30 PM – 12:37 PM PT
305 - Risk of Sexual Dysfunction in Men Treated with Pelvic Radiation Therapy for Locally Advanced Rectal Cancer: 20 Years of Experience with 430 PatientsLocation: Room 4Presenter: – Memorial Sloan Kettering Cancer Center
Kush Patel, BA, MBS – Memorial Sloan Kettering Cancer Center ### 1972036###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 12:40 PM – 12:47 PM PT
306 - Prognostic Role and Time Varying Failure Hazard of Neoadjuvant Rectal (NAR) Scores in the Stellar Randomized Phase 3 TrialLocation: Room 4Presenter: – Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
Yuan Tang, MD – Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College ### 2087162###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College###Presenter: – Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
### 12:50 PM – 12:57 PM PT
307 - Relationships between Microbiome and Response to Neoadjuvant Chemoradiotherapy in Rectal CancerLocation: Room 4Presenter: – Seoul National University Hospital
Bum Sup Jang, MD, PhD – Seoul National University Hospital ### 535816###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Seoul National University Hospital###Presenter: – Seoul National University Hospital
### 1:00 PM – 1:07 PM PT
308 - Long-Term Anorectal Function in Rectal Cancer Patients Managed by a Watch-and-Wait Strategy after Neoadjuvant Therapy: A Cross-Sectional StudyLocation: Room 4Presenter: – Fudan University Shanghai Cancer Center
Xin Jin, MD – Fudan University Shanghai Cancer Center ### 1972038###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Fudan University Shanghai Cancer Center###Presenter: – Fudan University Shanghai Cancer Center
### 1:10 PM – 1:17 PM PT
309 - Phase 1 Trial of SPECT-Guided Liver-Directed Ablative Radiotherapy for Patients with Low Functional Liver VolumeLocation: Room 4Presenter: – MD Anderson Cancer Center
Enoch Chang, MD – MD Anderson Cancer Center ### 747716###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###MD Anderson Cancer Center###Presenter: – MD Anderson Cancer Center
### 1:20 PM – 1:27 PM PT
310 - Stereotactic Body Radiotherapy Combined with Sintilimab in Patients with Recurrent or Oligometastatic Hepatocellular Carcinoma: A Phase II Clinical TrialLocation: Room 4Presenter: – Zhongshan Hospital Fudan University
Shisuo Du, MD, PhD – Zhongshan Hospital Fudan University ### 2130575###Presenter######Zhongshan Hospital Fudan University###Presenter: – Zhongshan Hospital Fudan University
### 1:30 PM – 1:45 PM PT
DiscussantLocation: Room 4Discussant: – Stanford University
Erqi Pollom, MD, MS – Stanford University ### 746577###Discussant###Disclosures: Employment: Stanford:Associate Professor:Employee | Compensation: Vysioneer: Advisory Board, Advisory Board Type, Advisory Board Proprietary-End Date: ongoing | Ownership: none | Leadership: none###Stanford University###Discussant: – Stanford University
### 12:50 PM – 12:57 PM PT
307 - Relationships between Microbiome and Response to Neoadjuvant Chemoradiotherapy in Rectal CancerLocation: Room 4Presenter: – Seoul National University Hospital
Hye In Lee, MD – Seoul National University Hospital ### 1972037###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Seoul National University Hospital###Presenter: – Seoul National University Hospital
### 1:30 PM – 1:40 PM PT
DiscussantLocation: Room 4Discussant: – Yale University School of Medicine
Kimberly Johung, MD, PhD – Yale University School of Medicine ### 524716###Discussant###Disclosures: Employment: Yale University School of Medicine: Associate Professor: Employee | Compensation: Role Topic Description-End Date: | Ownership: none | Leadership: none###Yale University School of Medicine###Discussant: – Yale University School of Medicine
### 12:30 PM – 12:37 PM PT
311 - Phase II Multi-Institutional Study of a Low-Dose (4Gy) Palliative Response-Adapted Radiotherapy Regimen for Symptomatic Bone Metastases from Multiple Myeloma: Planned Interim Analysis of First 40 PatiLocation: Room 5Presenter: – Cedars Sinai
Leslie Ballas, MD – Cedars Sinai ### 524742###Presenter###Disclosures: Employment: Cedars Sinai Medical Center:Physician:Employee | Compensation: Pfizer: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Compensation Payment-End Date: 11/11/22 ;Blue Earth: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Compensation Payment-End Date: 12/7/22 | Ownership: none | Leadership: none###Cedars Sinai###Presenter: – Cedars Sinai
### 12:40 PM – 12:47 PM PT
312 - Phase I Study of Bortezomib, Fludarabine, and Melphalan, with or without Total Marrow Irradiation As Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk or RLocation: Room 5Presenter: – City of Hope National Medical Center
Colton Ladbury, MD, BS – City of Hope National Medical Center ### 747995###Presenter###Disclosures: Employment: City of Hope National Medical Center:Resident Physician:Employee | Compensation: RefleXion Medical: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: Present | Ownership: none | Leadership: none###City of Hope National Medical Center###Presenter: – City of Hope National Medical Center
### 12:50 PM – 12:57 PM PT
313 - Predictors of Local Control with Palliative Radiotherapy for Multiple MyelomaLocation: Room 5
Robert Gao, MD – Mayo Clinic ### 524858###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Mayo Clinic###Presenter: – Mayo Clinic
### 1:00 PM – 1:07 PM PT
314 - Phase 2 Trial of Anti-PD1 and 8 Gy in 1 Fraction for Relapse/Refractory MyelomaLocation: Room 5Presenter: – Emory University
Mohammad Khan, MD, PhD – Emory University ### 1976471###Presenter###Disclosures: Employment: Emory University:Professor:Employee | Compensation: Merck Pharmaceuticals.: Research Grants, Research Funding, Research Salary Support, Grant Research Funding, Salary Support-End Date: 2025 ;Varian: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: 2022 | Ownership: none | Leadership: none###Emory University###Presenter: – Emory University
### 1:10 PM – 1:17 PM PT
315 - Radiation in a New Era of Multiple Myeloma Management: Patterns of Utilization, Clinical, Radiologic, and Biochemical Outcomes, and Possible Genomic Correlates of ResponseLocation: Room 5Presenter: – Memorial Sloan Kettering Cancer Center
Alexandra Dreyfuss, MD – Memorial Sloan Kettering Cancer Center ### 1972363###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 1:20 PM – 1:27 PM PT
316 - Clinical Outcome and Patterns of Failure in Patients with Solitary Plasmacytoma Treated with Radical RadiotherapyLocation: Room 5Presenter: – All India Institute of Medical Sciences
Ahitagni Biswas, MD, DNB, FRCR – All India Institute of Medical Sciences ### 535874###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###All India Institute of Medical Sciences###Presenter: – All India Institute of Medical Sciences
### 1:30 PM – 1:40 PM PT
DiscussantLocation: Room 5Discussant: – Institut Curie
Youlia Kirova, MD – Institut Curie ### 593453###Discussant###Disclosures: Employment: Institut Curie:Associate Professor Medical Doctor:Employee | Compensation: :Role Topic Description-End Date: | Ownership: none | Leadership: none###Institut Curie###Discussant: – Institut Curie
### 12:30 PM – 12:37 PM PT
298 - Landscape of the Radiosensitizing Properties of Targeted Agents from the NCI CTEP Portfolio across Genomically Diverse 3D Tumor ModelsLocation: Room 2Presenter: – Massachusetts General Hospital
Henning Willers, MD, FASTRO – Massachusetts General Hospital ### 535660###Presenter###Disclosures: Employment: Massachusetts General Hospital:Associate Radiation Oncologist:Employee;Massachusetts General Hospital:Assistant gynecologist:Employee;Harvard School of Public Health:Investigator:Employee | Compensation: NIH/NCI: Research Grants, Research Funding, Research Salary Support,Grant Research Funding-End Date: present ;Department of Defense: Research Grants, Research Funding, Research Salary Support,Grant Research Funding-End Date: present ;Apple Inc: Research Grants, Research Funding, Research Salary Support,Grant Research Funding-End Date: present | Ownership: none | Leadership: none###Massachusetts General Hospital###Presenter: – Massachusetts General Hospital
### 12:40 PM – 12:47 PM PT
299 - Intercellular Mechanisms of Therapeutic Resistance at the Tumor-Stromal Interface Using Ultra High-Plex Single-Cell Spatial Transcriptomics and Genetically-Engineered TumoroidsLocation: Room 2
Ryan Zhao, MD ### 2158963###Presenter#########Presenter:
### 12:50 PM – 12:57 PM PT
300 - Coupling In Vivo CRISPR Perturbation with Single Cell Transcriptomics Defines Gene-Treatment Interactions and Reveals the Role of DNA-PK as a Targetable Radiation Vulnerability in GlioblastomLocation: Room 2
S. John Liu, MD, PhD – UCSF ### 747161###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###UCSF###Presenter: – UCSF
### 1:00 PM – 1:07 PM PT
301 - Genetically Engineered Mouse Models of CIC-DUX4 Sarcoma Reveal an Unexpected Sensitivity to Histone Deacetylase (HDAC) InhibitionLocation: Room 2Presenter: – Duke University School of Medicine
Peter Hendrickson, MD, PhD – Duke University School of Medicine ### 1976472###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Duke University School of Medicine###Presenter: – Duke University School of Medicine
### 1:10 PM – 1:17 PM PT
302 - Enhancing Immune-Mediated Radiotherapy Efficacy in Murine Models of Head and Neck Cancer through Peroxisome Proliferator-Activated Receptor ModulationLocation: Room 2Presenter: – University of Colorado Anschutz Medical Campus
Richard Ross, MD – University of Colorado Anschutz Medical Campus ### 525097###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of Colorado Anschutz Medical Campus###Presenter: – University of Colorado Anschutz Medical Campus
### 1:20 PM – 1:27 PM PT
303 - Gamma Secretase Inhibition Sensitizes Pancreatic Adenocarcinoma Tumors to RT In VivoLocation: Room 2Presenter: – Thomas Jefferson University
Adam Mueller, MD, PhD – Thomas Jefferson University ### 746774###Presenter###Disclosures: Employment: Thomas Jefferson University:Assistant Professor:Employee | Compensation: Cosmocyte: Consultant, Uncompensated-End Date: to present ;ViewRay Corporation: Research Grants, Research Funding, Research Salary Support, Grant Research Funding, Salary Support-End Date: Present | Ownership: none | Leadership: none###Thomas Jefferson University###Presenter: – Thomas Jefferson University
### 1:30 PM – 1:37 PM PT
304 - Listeriolysin O Drives Innate and Adaptive Immune Responses to CD47 ImmunotherapyLocation: Room 2Presenter: – MD Anderson Cancer Center
Benjamin Schrank, MD, PhD – MD Anderson Cancer Center ### 1972198###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###MD Anderson Cancer Center###Presenter: – MD Anderson Cancer Center
###